ArticleCell communication and signaling : CCS2026
U2AF2-regulated alternative splicing of UPP1 promotes NSCLC progression by enhancing glycolysis.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
U2 small nuclear RNA auxiliary factor 2 (U2AF2), a key pre‑mRNA splicing factor whose role in NSCLC progression remains incompletely understood, was previously found by us to be significantly upregulated in non‑small cell lung cancer (NSCLC) tissues and to contribute to NSCLC progression‑related phenotypes. In this study, we observed that knockdown of U2AF2 induced exon 4-6 skipping in UPP1. Consistent with the role of U2AF2 in metabolic regulation, UPP1 was also found to modulate glycolysis‑related metabolic activity, with the UPP1‑L isoform exerting a more pronounced enhancement of glycolytic parameters, particularly under high glucose conditions. In vitro and in vivo functional assays showed that knockdown of UPP1‑L more strongly inhibited lung cancer cell growth and more robustly increased caspase‑dependent apoptosis than either control or UPP1‑S knockdown; Similarly, UPP1‑L knockdown caused a greater reduction in cancer cell migration and invasion and more clearly attenuated EMT‑associated phenotypes compared with UPP1‑S knockdown. Co‑IP assays indicated that UPP1‑L and UPP1‑S interact with partially distinct sets of proteins, which may at least partially underlie their differential functional effects in lung cancer cells. Analysis of clinical NSCLC samples further revealed a significant positive correlation between U2AF2 and UPP1‑L expression levels and showed that elevated UPP1‑L expression was significantly associated with poorer prognosis. Collectively, these findings identify a previously unrecognized role of U2AF2 in regulating UPP1 alternative splicing during NSCLC progression and suggest that modulation of UPP1 splicing may represent a potential therapeutic vulnerability in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.